GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Short Percentage of Float

NextCure (FRA:2US) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is NextCure Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of NextCure's Short Percentage of Float

For the Biotechnology subindustry, NextCure's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCure's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where NextCure's Short Percentage of Float falls into.


;
;

NextCure Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Short Percentage of Float
Comparable Companies
BRTX IMNN RLYB MRKR PSTV ERNA NERV GOVX PLRZ SYBX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
NXTC:USA
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
Website
https://www.nextcure.com
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Headlines

No Headlines